真皮注射交联透明质酸改善肤质的共识-《中国美容医学》

文章信息/Info

Title:: Consensus Recommendations on the Dermal Injection of Cross-linked Hyaluronic Acid To Improve Skin Texture

Author(s):: 31; 32)">China Dermatologist Association Aesthetic Injection Group 31; 32)">Dermatologists Branch of Guangdong Medical Doctors Association Dermatology and Surgery Group; Dermatologists Branch of Guangdong Medical Doctors Association Dermatology and Surgery Group

Keywords:: cross-linked hyaluronicacid; dermal injection; skin texture; dry skin and roughness; large pores; fine lines; acne scars

摘要:: 本共识所涉及的交联透明质酸(Cross-linked hyaluronicacid，CLHA)为小颗粒或较低浓度、低交联的透明质酸，一般采取真皮注射，主要用于改善皮肤干燥粗糙、毛孔粗大、细纹、痤疮瘢痕等肤质问题，与非交联HA相比持续时间更长。由于注射层次较浅，故严重不良反应的几率少；但由于产品特性和注射部位皮肤厚度差异大，需要操作者非常熟悉注射产品，严格掌握注射方法和单点用量，才能达到最佳的疗效并保证安全性。本文对真皮注射CLHA改善肤质相关的适应证、禁忌证、不同治疗目的及注射部位规范化治疗方案、常见不良反应及处理形成共识，以指导临床应用。

Abstract:: The Cross-linked hyaluronicacid (CLHA) mentioned in this consensus referred to small particle, low concentration or lower cross-linked products, which is also easy to inject in dermis but last longer than non cross-linked HA. The injection layer is intro-dermal, which is relatively safe with less serious adverse reactions. However, because the characteristics of the products and thickness of the skin in injection sites are various, the clinicians need to be very familiar with the products, and strictly control the injection method and amount in order to achieve the best results. This consensus focuses on the injection indications and contraindications, standardized treatment protocol for different treatment purposes and injection sites, common adverse reaction and solutions for clinical reference